Agogo-Mawuli, P.S.; Gross, J.D.; Setola, V.; Gall, B.J.; Siderovski, D.P.
Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence. Int. J. Mol. Sci. 2025, 26, 11993.
https://doi.org/10.3390/ijms262411993
AMA Style
Agogo-Mawuli PS, Gross JD, Setola V, Gall BJ, Siderovski DP.
Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence. International Journal of Molecular Sciences. 2025; 26(24):11993.
https://doi.org/10.3390/ijms262411993
Chicago/Turabian Style
Agogo-Mawuli, Percy S., Joshua D. Gross, Vincent Setola, Bryan J. Gall, and David P. Siderovski.
2025. "Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence" International Journal of Molecular Sciences 26, no. 24: 11993.
https://doi.org/10.3390/ijms262411993
APA Style
Agogo-Mawuli, P. S., Gross, J. D., Setola, V., Gall, B. J., & Siderovski, D. P.
(2025). Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence. International Journal of Molecular Sciences, 26(24), 11993.
https://doi.org/10.3390/ijms262411993
